This report was first published by Endpoints News. To see the original version, click here
Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early research and work in the clinic.
Soon after, Novo trimmed several programs from its pipeline. The company later exited the cell therapy field, further sharpening its focus on diabetes and obesity, along with related comorbidities.
您已阅读7%（498字），剩余93%（7118字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。